Surgical site infections (SSIs) are a significant financial burden for hospitals, costing an estimated $3.3 billion annually. A biotech company, PolyPid, is addressing this issue with its lead drug D-PLEX100, which aims to reduce these infections post-surgery. This product, which delivers the antibiotic doxycycline directly to the surgical site, is currently awaiting FDA approval with decisions expected in early 2027. Clinical trial results show promising reductions in infection rates, indicating potential benefits for hospitals facing new Medicare payment models that penalize high infection rates. PolyPid is also in advanced partnership discussions for commercializing D-PLEX100, along with an expanding pipeline of drug-delivery technologies.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.benzinga.com/content/60439967/surgical-infections-cost-hospitals-billions-one-under-radar-biotech-player-might-be-about-change
